Library
Research library
Articles on peptide research topics, written on the same standard as the product dossiers: model-anchored, reference-backed, every source a resolvable link.
Ipamorelin and CJC-1295 (mod GRF 1-29): A Comparative Review of the Growth-Hormone-Axis Research Literature
A neutral comparison of two peptides studied alongside one another for their effects on the growth-hormone axis, spanning animal, human, and analytical work. The evidence base is fragmentary and largely preclinical or forensic; controlled human data are scarce.
SS-31 (Elamipretide): Mitochondrial Cardiolipin Targeting and the State of the Research
An evidence-first profile of SS-31 (elamipretide), a mitochondria-targeting tetrapeptide studied for cardiolipin binding in preclinical models and a small number of human trials in rare mitochondrial disorders. The clinical evidence base remains limited and disease-specific.
BPC-157 (Body Protection Compound 157): Research Profile and Study Landscape
An evidence-first overview of BPC-157, a synthetic pentadecapeptide studied chiefly in preclinical models of tissue injury and musculoskeletal healing. The literature remains predominantly animal and in vitro, with controlled human data described as lacking.
BPC-157 and TB-500 (Thymosin beta-4): A Comparative Review of Co-Studied Tissue-Repair Peptides
A neutral comparison of two peptides frequently examined in overlapping tissue-repair and inflammation research contexts. The evidence base is predominantly preclinical—animal and in vitro—with limited controlled human data for either compound.
MOTS-c: Research Profile of a Mitochondrial-Derived Peptide in Metabolic and Cardiopulmonary Models
An evidence-first overview of MOTS-c, a 16-amino-acid mitochondrial-derived peptide studied in exercise physiology, metabolic, and organ-injury models. The literature is predominantly preclinical, with limited human observational data.
TB-500 (Thymosin beta-4): Research Profile and Study Landscape
An evidence-first overview of Thymosin beta-4 (TB-500), covering its identity as an actin-regulating peptide and the preclinical models—cell culture, organoid, and rodent—in which it has been studied. The cited evidence base is predominantly in vitro and animal.